SUMMARY
During atherosclerosis plaque progression, pathological intraplaque angiogenesis leads to plaque rupture accompanied by thrombosis, which is probably the most important cause of arteries complications such as cerebral and myocardial infarction. Even though few treatments are available to mitigate plaque rupture, further investigation is required to develop a robust optimized therapeutic method. In this study using rabbit and mouse atherosclerotic models, sinoporphyrin sodium (DVDMS)-mediated sonodynamic therapy reduced abnormal angiogenesis and plaque rupture. Briefly, DVDMS is injected to animals, and then the plaque was locally exposed to pulse ultrasound for a few minutes. Furthermore, a small size clinical trial was conducted on patients with atherosclerosis. Notably, a significant reduction of arterial inflammation and angiogenesis was recorded following a short period of DVDMS-mediated sonodynamic therapy treatment. This beneficial outcome was almost equivalent to the therapeutic outcome after 3-month intensive statin treatment. 
P athological angiogenesis is a crucial
factor that leads to vulnerable atherosclerotic plaque rupture (1) . Thus, inhibition of plaque neovascularization provides an important therapeutic strategy to minimize or even prevent vulnerable lesion disruption and subsequent atherothrombotic complications.
Vascular endothelial growth factor A (VEGF-A), a well-known hypoxia-inducible factor (HIF) target gene, constitutes the main regulator of neovascularization (2) . To date, VEGF-A inhibitors have been used as systemic medications that directly exert an effect on endothelial cells to inhibit angiogenesis in cancer chemotherapy. However, the use of current VEGF-A blockers results in severe or even fatal off-target effects, such as hypertension and thromboembolism, because of the disruption of endothelial homeostasis (3) (4) (5) . Therefore, a site-specific treatment that indirectly targets neovessel endothelial cells may present a safer and more feasible alternative to suppress plaque neovascularization.
Pathological neovessels induce intraplaque hemorrhage and inflammatory signals that result in the infiltration of macrophages into atherosclerotic plaques (6) . In turn, these macrophages secrete VEGF-A on HIF-1a activation to promote pathological angiogenesis, vascular permeability, and inflammatory cell recruitment (7) . The mutual exacerbation of pathological neovascularization and macrophage-mediated inflammation triggers plaque rupture (1, 8 Fisher exact test was performed to analyze the qualitative data. All p < 0.05 were considered statistically significant.
RESULTS

DVDMS-SDT SUPPRESSES NEOVASCULARIZATION AND INCREASES THE STABILITY OF RABBIT AND MOUSE ADVANCED ATHEROSCLEROTIC PLAQUE.
Therapeutic ultrasound was utilized on rabbit pla- Figure 5A) . The heat map showed that DVDMS-SDT down-regulated a number of genes associated with angiogenesis signaling including HIF-1A, which was blocked by caspase 3-specific inhibitor Ac-DEVD-CHO ( Figure 5B) .
Studies have well established that HIF-1a promotes
VEGF-A expression (13, 14) . In the present study, we confirmed that DVDMS-SDT reduced both messenger ribonucleic acid and protein levels of HIF-1a and 5C and 5D ) by activating caspase 3, which was reversed by HIF-1a overexpression ( Figures 6A and 6B ).
VEGF-A (Figures
However, we found no direct regulatory effect of caspase 3 on HIF-1a. Therefore, we hypothesized that Figure 6D) .
Therefore, our finding validated that SP-1 bound to the HIF1A promoter region ( Figure 6E ) and promoted HIF1A transcription in THP-1-derived foam cells ( Figure 6F) . Subsequent ChIP-quantitative polymerase chain reaction showed that the interaction of SP-1 with the HIF1A promoter diminished significantly on DVDMS-SDT treatment ( Figure 6G ). In addition, caspase 3 activated by DVDMS-SDT cleaved SP-1, but not androgen receptor, CTNNB1, and MDM2 (Supplemental Figure 7) , leading to reduced HIF-1a expression ( Figures 6H to 6M) ; which was reversed by 6N to 6P) . Supplemental Tables 3A and 3C .
SP-1 overexpression (Figures
In the stage 1 study, no significant difference in blood test parameters was observed after DVDMS-SDT treatment ( Supplemental Table 3B ). In the stage 2 study, the normalized MVE in plaque at 1 month after ( Figures 8E to 8N) . 
